… Rivaroxaban (20 mg/15 mg once daily) is an effective and safe alternative to warfarin for
stroke prevention in patients with non-valvular AF (NVAF). Low-dose rivaroxaban (15 mg/10 mg …

… between use of apixaban, dabigatran, and rivaroxaban and risk of stroke or systemic
embolism and major bleeding among patients with non-valvular atrial fibrillation (NVAF). …

… rivaroxaban in secondary VTE prevention has been proven previously in a well-controlled
study 29 . Our results imply that rivaroxaban treatment … in patients treated with rivaroxaban. In …

… valve disease subgroups in patients with non-valvular AF treated with oral anticoagulation.
… from a pharmacovigilance study of rivaroxaban with non-valvular AF that excluded patients …

… Rivaroxaban is a selective oral direct factor Xa … non-valvular AF (NVAF). Non-randomized
studies suggest that it may be feasible to manage patients undergoing CA with rivaroxaban. …

… part of the spectrum of non-valvular AF to which the … of rivaroxaban is concerned. The type
of patients included in this trial corresponds to the definition of non-valvular atrial fibrillation as …

… system to predict stroke in patients with non-valvular atrial fibrillation (AF). This post hoc … ,
and the relative effectiveness and safety of rivaroxaban vs. warfarin in patients with and without …

… Rivaroxaban is an oral anticoagulant approved in the US for prevention of … non-valvular
atrial fibrillation (NVAF). We determined the effectiveness and associated risks of rivaroxaban …

… among non-valvular atrial fibrillation (NVAF) patients on rivaroxaban … treatment altogether
compared to 168 days for patients initiating rivaroxaban treatment, suggesting that rivaroxaban …

… of rivaroxaban vs. warfarin in non-valvular atrial fibrillation (NVAF) patients with concomitant
… artery disease (CAD) and/or peripheral artery disease (PAD) treated in routine practice. …